Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Deep immune signature of immune-mediated aplastic anemia patients shows distinct subsets of regulatory T cells associated with response to treatment: Results from the phase 3, randomized EBMT race clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

SGSıla GerlevikGNGiorgio NapolitaniRCRiley Cook

Discussion

Loading...

Member takes

Overview

Randomized clinical trial identified T-cell signatures predicting treatment response in aplastic anemia, highlighting the role of regulatory T cells.

Key Points

  • The study aims to identify immune signatures that predict treatment response in patients with immune-mediated aplastic anemia.
  • Conducted a randomized phase-3 trial on 130 severely untreated AA patients with hATG + CsA treatment, with or without EPAG.
  • Utilized mass cytometry to analyze T-cell, B cell, myeloid, and NK cell frequencies in patients at diagnosis and after 6 months.
  • Employed multinomial and multivariable logistic regression to identify predictive features related to immune cell subsets.
  • Broad immune dysregulation was observed, characterized by reduced myeloid and NK cell frequencies, and expanded effector T-cell subsets.
  • Naïve Tregs were enriched in patients achieving complete response, whereas memory Tregs were more prevalent in non-responders.
  • Both treatment arms showed increased frequencies of myeloid cells and NK cells at 6 months, indicating improved hematopoiesis.

Cite This Study

Gerlevik et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5f6https://doi.org/10.1182/blood-2025-26
View Full Paper
Ask AI
Bookmark
Share